Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiwu Lin

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Discover Oncology|January 30, 2026
Exploring the mechanism and therapeutic potential of BUB1 in regulating esophageal cancer progression based on 5-FU target predictionLiangqin Luo, ZhiWu Lin, Zitong Xiong, et al.
Scientific Reports|April 8, 2024
Analyzing the changing trend of corneal biomechanical properties under different influencing factors in T2DM patientsJuan Tang, Zhiwu Lin, Xingde Liu, et al.
Plos One|September 2, 2016
Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous CarcinomaXiufeng Wu, Zhenzhen Zhang, Xin Li, et al.
Discover Oncology|April 11, 2025
Identification of the disulfidptosis-related key gene CD2AP as a potential biomarker and new therapeutic target for LUAD patients by comprehensive multi-omics analysisZhiwu Lin, Jing Lv, Chuanqiang Dai, et al.
Discover Oncology|April 24, 2025
Knowledge map of programmed cell death in esophageal cancer: a bibliometric analysisRulin Li, Yanchun Yang, Yang Gao, et al.
Journal of Lipid Research|October 11, 2008
The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and bindingOmar L Francone, Meihua Tu, Lori J Royer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 2017
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical OutcomeJennifer Q Dong, James R Gosset, Odette A Fahmi, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitorsJeffrey A Pfefferkorn, Chulho Choi, Yuntao Song, et al.
Journal of Medicinal Chemistry|December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemiaJeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsWilliam K C Park, Robert M Kennedy, Scott D Larsen, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Discover Oncology|January 30, 2026
Exploring the mechanism and therapeutic potential of BUB1 in regulating esophageal cancer progression based on 5-FU target predictionLiangqin Luo, ZhiWu Lin, Zitong Xiong, et al.
Scientific Reports|April 8, 2024
Analyzing the changing trend of corneal biomechanical properties under different influencing factors in T2DM patientsJuan Tang, Zhiwu Lin, Xingde Liu, et al.
Plos One|September 2, 2016
Poorer Prognosis of Primary Signet-Ring Cell Carcinoma of the Breast Compared with Mucinous CarcinomaXiufeng Wu, Zhenzhen Zhang, Xin Li, et al.
Discover Oncology|April 11, 2025
Identification of the disulfidptosis-related key gene CD2AP as a potential biomarker and new therapeutic target for LUAD patients by comprehensive multi-omics analysisZhiwu Lin, Jing Lv, Chuanqiang Dai, et al.
Discover Oncology|April 24, 2025
Knowledge map of programmed cell death in esophageal cancer: a bibliometric analysisRulin Li, Yanchun Yang, Yang Gao, et al.
Journal of Lipid Research|October 11, 2008
The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and bindingOmar L Francone, Meihua Tu, Lori J Royer, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 4, 2017
Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical OutcomeJennifer Q Dong, James R Gosset, Odette A Fahmi, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2007
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitorsJeffrey A Pfefferkorn, Chulho Choi, Yuntao Song, et al.
Journal of Medicinal Chemistry|December 13, 2007
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemiaJeffrey A Pfefferkorn, Chulho Choi, Scott D Larsen, et al.
Bioorganic & Medicinal Chemistry Letters|December 25, 2007
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitorsWilliam K C Park, Robert M Kennedy, Scott D Larsen, et al.
Pageof 3